This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glück, U.
Right arrow Articles by Glück, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glück, U.
Right arrow Articles by Glück, R.

 Previous Article  |  Next Article 

Journal of Virology, September 1999, p. 7780-7786, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Phase 1 Evaluation of Intranasal Virosomal Influenza Vaccine with and without Escherichia coli Heat-Labile Toxin in Adult Volunteers

Ulrich Glück,1 Jan-Olaf Gebbers,2 and Reinhard Glück3,*

Division of Occupational Medicine, SUVA Swiss National Accident Insurance Institute, CH-6002 Lucerne,1 Institute of Pathology, Cantonal Hospital, CH-6000 Lucerne 16,2 and Department of Virology, Swiss Serum & Vaccine Institute Berne, CH-3001 Berne,3 Switzerland

Received 19 February 1999/Accepted 19 May 1999

Virosomal vaccines were prepared by extracting hemagglutinin (HA) and neuraminidase from influenza virus and incorporating it in the membranes of liposomes composed of phosphatidylcholine. Two intranasal spray vaccine series were prepared: one series comprised 7.5 µg of HA of each of three strains recommended by the World Health Organization and 1 µg of Escherichia coli heat-labile toxin (HLT), and the other contained the HA without HLT. In addition, a third vaccine preparation contained 15 µg of HA and 2 µg of HLT. The parenteral virosomal vaccine contained 15 µg of HA without additional adjuvant. The immunogenicity of a single spray vaccination (15 µg of HA and 2 µg of HLT) was compared with that of two vaccinations (7.5 µg of HA with or without 1 µg of HLT) with an interval of 1 week in 60 healthy working adults. Twenty volunteers received one parenteral virosomal vaccine. Two nasal spray vaccinations with HLT-adjuvanted virosomal influenza vaccine induced a humoral immune response which was comparable to that with a single parenteral vaccination. A significantly higher induction of influenza virus-specific immunoglobulin A was noted in the saliva after two nasal applications. The immune response after a single spray vaccination was significantly lower. It could be shown that the use of HLT as a mucosal adjuvant is necessary to obtain a humoral immune response comparable to that with parenteral vaccination. All vaccines were well tolerated.

* Corresponding author. Mailing address: Swiss Serum & Vaccine Institute Berne, P.O. Box, CH-3001 Berne, Switzerland. Phone: 41-31-885111. Fax: 41-31-8885181. E-mail: r.glueck{at}bluewin.ch.

Journal of Virology, September 1999, p. 7780-7786, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Koizumi, Y., Kurita-Ochiai, T., Oguchi, S., Yamamoto, M. (2008). Nasal Immunization with Porphyromonas gingivalis Outer Membrane Protein Decreases P. gingivalis-Induced Atherosclerosis and Inflammation in Spontaneously Hyperlipidemic Mice. Infect. Immun. 76: 2958-2965 [Abstract] [Full Text]  
  • Abd Alla, M. D., White, G. L., Rogers, T. B., Cary, M. E., Carey, D. W., Ravdin, J. I. (2007). Adherence-Inhibitory Intestinal Immunoglobulin A Antibody Response in Baboons Elicited by Use of a Synthetic Intranasal Lectin-Based Amebiasis Subunit Vaccine. Infect. Immun. 75: 3812-3822 [Abstract] [Full Text]  
  • Bertot, G. M., Restelli, M. A., Galanternik, L., Aranibar Urey, R. C., Valvano, M. A., Grinstein, S. (2007). Nasal Immunization with Burkholderia multivorans Outer Membrane Proteins and the Mucosal Adjuvant Adamantylamide Dipeptide Confers Efficient Protection against Experimental Lung Infections with B. multivorans and B. cenocepacia. Infect. Immun. 75: 2740-2752 [Abstract] [Full Text]  
  • Stephenson, I., Zambon, M. C., Rudin, A., Colegate, A., Podda, A., Bugarini, R., del Giudice, G., Minutello, A., Bonnington, S., Holmgren, J., Mills, K. H. G., Nicholson, K. G. (2006). Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers.. J. Virol. 80: 4962-4970 [Abstract] [Full Text]  
  • van Ginkel, F. W., Jackson, R. J., Yoshino, N., Hagiwara, Y., Metzger, D. J., Connell, T. D., Vu, H. L., Martin, M., Fujihashi, K., McGhee, J. R. (2005). Enterotoxin-Based Mucosal Adjuvants Alter Antigen Trafficking and Induce Inflammatory Responses in the Nasal Tract. Infect. Immun. 73: 6892-6902 [Abstract] [Full Text]  
  • Eriksson, A. M., Schon, K. M., Lycke, N. Y. (2004). The Cholera Toxin-Derived CTA1-DD Vaccine Adjuvant Administered Intranasally Does Not Cause Inflammation or Accumulate in the Nervous Tissues. J. Immunol. 173: 3310-3319 [Abstract] [Full Text]  
  • Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., Steffen, R. (2004). Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland. NEJM 350: 896-903 [Abstract] [Full Text]  
  • Olszewska, W., Zambon, M., Openshaw, P. J M (2002). Development of vaccines against common colds. Br Med Bull 62: 99-111 [Abstract] [Full Text]  
  • Chen, D., Periwal, S. B., Larrivee, K., Zuleger, C., Erickson, C. A., Endres, R. L., Payne, L. G. (2001). Serum and Mucosal Immune Responses to an Inactivated Influenza Virus Vaccine Induced by Epidermal Powder Immunization. J. Virol. 75: 7956-7965 [Abstract] [Full Text]  
  • Stephenson, I., Nicholson, K.G. (2001). Influenza: vaccination and treatment. Eur Respir J 17: 1282-1293 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»